MedTrace Logo

Switching Medication and Augmentation Strategies for SSRI-Resistant Adolescent Depression（SMART-I)

NCT07011693 · Status: NOT_YET_RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 400

Last updated 2025-06-10

No results posted yet for this study

Summary

This project aims to investigate the effectiveness of existing common antidepressants in adolescents with MDD who did not respond to their first treatment.

Conditions

  • Major Depressive Disorder (MDD)

Interventions

DRUG

Sertraline

Commonly used oral antipsychotics intervention therapy.

DRUG

Agomelatine

Commonly used oral antipsychotics intervention therapy.

DRUG

Aripiprazole

Commonly used oral antipsychotics intervention therapy.

Sponsors & Collaborators

  • Xinyu Zhou

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
12 Years
Max Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-06-20
Primary Completion
2027-06-30
Completion
2027-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07011693 on ClinicalTrials.gov